KR20110079564A - Composition for activating mitochondria containing ginseng berry extracts - Google Patents
Composition for activating mitochondria containing ginseng berry extracts Download PDFInfo
- Publication number
- KR20110079564A KR20110079564A KR1020100139838A KR20100139838A KR20110079564A KR 20110079564 A KR20110079564 A KR 20110079564A KR 1020100139838 A KR1020100139838 A KR 1020100139838A KR 20100139838 A KR20100139838 A KR 20100139838A KR 20110079564 A KR20110079564 A KR 20110079564A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- diseases
- ginseng fruit
- extract
- mitochondrial
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 85
- 241000208340 Araliaceae Species 0.000 title claims abstract description 82
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 82
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 82
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 82
- 239000000284 extract Substances 0.000 title claims abstract description 77
- 210000003470 mitochondria Anatomy 0.000 title claims abstract description 24
- 230000003213 activating effect Effects 0.000 title description 4
- 235000021028 berry Nutrition 0.000 title description 2
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 77
- 230000004913 activation Effects 0.000 claims abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- 210000003205 muscle Anatomy 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 235000013402 health food Nutrition 0.000 claims abstract description 6
- 238000011084 recovery Methods 0.000 claims abstract description 6
- 208000014644 Brain disease Diseases 0.000 claims abstract description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 208000016222 Pancreatic disease Diseases 0.000 claims abstract description 4
- 208000019622 heart disease Diseases 0.000 claims abstract description 4
- 208000019423 liver disease Diseases 0.000 claims abstract description 4
- 208000024691 pancreas disease Diseases 0.000 claims abstract description 3
- 238000005728 strengthening Methods 0.000 claims abstract 2
- 230000002438 mitochondrial effect Effects 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 16
- 230000002265 prevention Effects 0.000 claims description 9
- 241000283690 Bos taurus Species 0.000 claims description 5
- 206010010904 Convulsion Diseases 0.000 claims description 3
- 208000029578 Muscle disease Diseases 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 3
- 208000025966 Neurological disease Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 206010003591 Ataxia Diseases 0.000 claims description 2
- 206010003694 Atrophy Diseases 0.000 claims description 2
- 206010003805 Autism Diseases 0.000 claims description 2
- 208000020706 Autistic disease Diseases 0.000 claims description 2
- 201000004569 Blindness Diseases 0.000 claims description 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 2
- 206010010774 Constipation Diseases 0.000 claims description 2
- 206010011878 Deafness Diseases 0.000 claims description 2
- 206010012559 Developmental delay Diseases 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- 208000012661 Dyskinesia Diseases 0.000 claims description 2
- 206010015995 Eyelid ptosis Diseases 0.000 claims description 2
- 206010019663 Hepatic failure Diseases 0.000 claims description 2
- 208000013016 Hypoglycemia Diseases 0.000 claims description 2
- 208000001953 Hypotension Diseases 0.000 claims description 2
- 208000036626 Mental retardation Diseases 0.000 claims description 2
- 208000000112 Myalgia Diseases 0.000 claims description 2
- 208000004350 Strabismus Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 230000037444 atrophy Effects 0.000 claims description 2
- 230000002567 autonomic effect Effects 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 2
- 230000010370 hearing loss Effects 0.000 claims description 2
- 231100000888 hearing loss Toxicity 0.000 claims description 2
- 208000016354 hearing loss disease Diseases 0.000 claims description 2
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 2
- 230000036543 hypotension Effects 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 208000007903 liver failure Diseases 0.000 claims description 2
- 231100000835 liver failure Toxicity 0.000 claims description 2
- 201000006938 muscular dystrophy Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 210000001328 optic nerve Anatomy 0.000 claims description 2
- 230000000849 parathyroid Effects 0.000 claims description 2
- 201000003004 ptosis Diseases 0.000 claims description 2
- 230000002207 retinal effect Effects 0.000 claims description 2
- 206010042772 syncope Diseases 0.000 claims description 2
- 208000007101 Muscle Cramp Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 206010030875 ophthalmoplegia Diseases 0.000 claims 1
- 230000011514 reflex Effects 0.000 claims 1
- 108020005196 Mitochondrial DNA Proteins 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 10
- 102000004190 Enzymes Human genes 0.000 abstract description 3
- 108090000790 Enzymes Proteins 0.000 abstract description 3
- 206010029216 Nervousness Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 15
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 14
- 239000000796 flavoring agent Substances 0.000 description 12
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 9
- 235000019634 flavors Nutrition 0.000 description 9
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 9
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 229930182555 Penicillin Natural products 0.000 description 7
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 7
- 229910002091 carbon monoxide Inorganic materials 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 229940107131 ginseng root Drugs 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 229940049954 penicillin Drugs 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000007901 soft capsule Substances 0.000 description 7
- 229960005322 streptomycin Drugs 0.000 description 7
- 235000002789 Panax ginseng Nutrition 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 5
- 229930003268 Vitamin C Natural products 0.000 description 5
- 229930003427 Vitamin E Natural products 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 230000002500 effect on skin Effects 0.000 description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 5
- 229960001031 glucose Drugs 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- 235000019154 vitamin C Nutrition 0.000 description 5
- 239000011718 vitamin C Substances 0.000 description 5
- 235000019165 vitamin E Nutrition 0.000 description 5
- 229940046009 vitamin E Drugs 0.000 description 5
- 239000011709 vitamin E Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000005778 DNA damage Effects 0.000 description 4
- 231100000277 DNA damage Toxicity 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 229930182494 ginsenoside Natural products 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 210000001700 mitochondrial membrane Anatomy 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- HHZQLQREDATOBM-CODXZCKSSA-M Hydrocortisone Sodium Succinate Chemical compound [Na+].O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC([O-])=O)[C@@H]4[C@@H]3CCC2=C1 HHZQLQREDATOBM-CODXZCKSSA-M 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 150000004781 alginic acids Chemical class 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 229940077731 carbohydrate nutrients Drugs 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 235000015203 fruit juice Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 210000000663 muscle cell Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 230000002407 ATP formation Effects 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 240000000560 Citrus x paradisi Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- AGBCLJAHARWNLA-DQUQINEDSA-N Ginsenoside Rg2 Natural products O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@@](C)(O)CCC=C(C)C)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O AGBCLJAHARWNLA-DQUQINEDSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 108091093105 Nuclear DNA Proteins 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 2
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- -1 external preparation Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940089161 ginsenoside Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 235000021283 resveratrol Nutrition 0.000 description 2
- 229940016667 resveratrol Drugs 0.000 description 2
- 229910052702 rhenium Inorganic materials 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 235000016804 zinc Nutrition 0.000 description 2
- AGBCLJAHARWNLA-UHFFFAOYSA-N (20R)-ginsenoside Rg2 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C3C(C)(C)C(O)CCC3(C)C3C(C4(CCC(C4C(O)C3)C(C)(O)CCC=C(C)C)C)(C)C2)OC(CO)C(O)C1O AGBCLJAHARWNLA-UHFFFAOYSA-N 0.000 description 1
- AUHDWARTFSKSAC-HEIFUQTGSA-N (2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-(6-oxo-1H-purin-9-yl)oxolane-2-carboxylic acid Chemical compound [C@]1([C@H](O)[C@H](O)[C@@H](CO)O1)(N1C=NC=2C(O)=NC=NC12)C(=O)O AUHDWARTFSKSAC-HEIFUQTGSA-N 0.000 description 1
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- QWJSAWXRUVVRLH-LREBCSMRSA-M 2-hydroxyethyl(trimethyl)azanium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound C[N+](C)(C)CCO.OC(=O)[C@H](O)[C@@H](O)C([O-])=O QWJSAWXRUVVRLH-LREBCSMRSA-M 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000000187 Abnormal Reflex Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- YPZRHBJKEMOYQH-UYBVJOGSSA-L FADH2(2-) Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP([O-])(=O)OP([O-])(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C(NC(=O)NC2=O)=C2NC2=C1C=C(C)C(C)=C2 YPZRHBJKEMOYQH-UYBVJOGSSA-L 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 102100039869 Histone H2B type F-S Human genes 0.000 description 1
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GRSZFWQUAKGDAV-UHFFFAOYSA-N Inosinic acid Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010052641 Mitochondrial DNA mutation Diseases 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 108010041191 Sirtuin 1 Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- FRHBOQMZUOWXQL-UHFFFAOYSA-L ammonium ferric citrate Chemical compound [NH4+].[Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FRHBOQMZUOWXQL-UHFFFAOYSA-L 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000011640 ferrous citrate Substances 0.000 description 1
- 235000019850 ferrous citrate Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 1
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 1
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 1
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 235000013902 inosinic acid Nutrition 0.000 description 1
- 239000004245 inosinic acid Substances 0.000 description 1
- 229940028843 inosinic acid Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000004313 iron ammonium citrate Substances 0.000 description 1
- 235000000011 iron ammonium citrate Nutrition 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- IKEOZQLIVHGQLJ-UHFFFAOYSA-M mitoTracker Red Chemical compound [Cl-].C1=CC(CCl)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 IKEOZQLIVHGQLJ-UHFFFAOYSA-M 0.000 description 1
- 208000012268 mitochondrial disease Diseases 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- JURZHOVRCOWZFN-UHFFFAOYSA-N notoginsenoside R1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(CC34C)OC6OC(COC7OCC(O)C(O)C7O)C(O)C(O)C6O)C JURZHOVRCOWZFN-UHFFFAOYSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- SWQINCWATANGKN-UHFFFAOYSA-N protopanaxadiol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC1C3(C)CCC(O)C(C)(C)C3CCC21C SWQINCWATANGKN-UHFFFAOYSA-N 0.000 description 1
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- WTWSHHITWMVLBX-DKWTVANSSA-M sodium;(2s)-2-aminobutanedioate;hydron Chemical compound [Na+].[O-]C(=O)[C@@H](N)CC(O)=O WTWSHHITWMVLBX-DKWTVANSSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 235000021195 test diet Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 미토콘드리아 활성화를 위한 조성물에 관한 것으로, 보다 상세하게는 인삼 열매 추출물을 유효성분으로 함유함으로써 미토콘드리아 관련 효소의 활성 및 미토콘드리아 DNA의 양을 증가시키고 근력을 강화시키며 피로 회복을 촉진시키는 미토콘드리아 활성화를 위한 조성물에 관한 것이다.
The present invention relates to a composition for mitochondrial activation, and more particularly, by containing ginseng fruit extract as an active ingredient, mitochondrial activation, which increases the activity of mitochondrial-related enzymes and the amount of mitochondrial DNA, strengthens muscle strength and promotes fatigue recovery. It relates to a composition for.
미토콘드리아(mitochondria)는 세포 내 소기관으로 대부분의 진핵세포에 존재하며, 핵 DNA와 분리되는 자체적인 DNA인 미토콘드리아 DNA(mtDNA)를 가진다. Mitochondria are intracellular organelles present in most eukaryotic cells and have their own mitochondrial DNA (mtDNA), which is separated from nuclear DNA.
미토콘드리아의 주요 기능은 세포 내 에너지원인 ATP를 생성하는 것이다. ATP는 미토콘드리아의 기질 내 TCA 회로를 통해 생성되는 NADH, FADH2를 사용해 전자전달계에서 생성된다. 이렇게 생성된 ATP는 다양한 에너지-요구 생합성 및 여러 가지 대사 활성을 추진시키는 데 사용된다. The main function of mitochondria is to produce ATP, an intracellular energy source. ATP is produced in the electron transport system using NADH, FADH2, which is produced through the TCA circuit in the substrate of the mitochondria. The ATP thus produced is used to drive various energy-required biosynthesis and various metabolic activities.
또한, 미토콘드리아는 세포 내 신호전달에 중요한 역할을 하는 칼슘이온을 기질 내에 저장하고 있다가 필요시에 세포질로 공급하는 역할을 하기도 한다. 이 밖에도 세포 사멸, 증식 및 대사 등을 조절하는 역할을 하는 것으로 알려져 있다. In addition, mitochondria store calcium ions in the substrate, which play an important role in intracellular signal transduction, and also supply the cytoplasm when necessary. In addition, it is known to play a role in regulating cell death, proliferation and metabolism.
더욱이, mtDNA는 세포의 핵 DNA와는 달리 자체적인 수선 기작(repair mechanism)이 없으며, DNA를 보호하는 역할을 하는 히스톤 단백질이 없기 때문에 상대적으로 손상되기 쉽다. 이러한 mtDNA의 손상은 미토콘드리아 질환의 발병과도 밀접한 관련이 있는 것으로 알려져 있으며, 미토콘드리아의 기능 저하로 연결되어 세포 활동에 필요한 에너지원인 ATP 합성이 감소하게 되고, 다양한 질환 발병의 원인이 된다.
Moreover, unlike nuclear DNA of cells, mtDNA does not have its own repair mechanism and is relatively fragile because there is no histone protein that protects DNA. The damage of mtDNA is known to be closely related to the development of mitochondrial disease, leading to a decrease in the function of mitochondria, reducing the synthesis of ATP, which is an energy source necessary for cell activity, and causes various diseases.
이에, 본 발명자들은 인삼의 지상부인 인삼 열매 추출물이 일반적인 인삼 및 홍삼과는 다른 성분과 조성으로 인해 미토콘드리아 관련 효소의 활성 및 미토콘드리아 DNA 양을 증가시키고, 미토콘드리아를 활성화시키며, 미토콘드리아 막전위를 감소시키고, NAD+/NADH 비를 증가시키며 자외선 조사에 의한 미토콘드리아 DNA 손상을 저해시킴으로써 근력을 강화하고 피로 회복을 촉진시킬 수 있음을 발견하고, 본 발명을 완성하게 되었다.Thus, the inventors of the present invention, the ginseng fruit extract of the ground portion of ginseng increases the activity of mitochondrial-related enzymes and mitochondrial DNA, activating mitochondria, reducing mitochondrial membrane potential, NAD due to different components and composition than general ginseng and red ginseng The present invention was completed by increasing the ratio of + / NADH and inhibiting mitochondrial DNA damage by ultraviolet irradiation, thereby enhancing muscle strength and promoting fatigue recovery.
따라서, 본 발명의 목적은 미토콘드리아 활성화를 위한 조성물을 제공하는 것이다.
It is therefore an object of the present invention to provide a composition for mitochondrial activation.
상기한 목적을 달성하기 위하여, 본 발명에서는 인삼 열매 추출물을 유효성분으로 함유하는 미토콘드리아 활성화를 위한 조성물을 제공한다.
In order to achieve the above object, the present invention provides a composition for activating mitochondria containing ginseng fruit extract as an active ingredient.
본 발명에 따른 미토콘드리아 활성화를 위한 미토콘드리아 DNA의 복제수(copy number)를 현저하게 증가시켰으며, 근력을 강화시켰고, 미토콘드리아 막전위를 감소시키고, NAD+/NADH 비를 증가시키며 자외선 조사에 의한 미토콘드리아 DNA 손상을 저해하였다.Significantly increased the copy number of mitochondrial DNA for mitochondrial activation according to the present invention, strengthened muscle strength, decreased mitochondrial membrane potential, increased NAD + / NADH ratio and damaged mitochondrial DNA by UV irradiation Inhibited.
이를 통해, 본 발명에 따른 조성물은 미토콘드리아 기능 저하와 관련하여 발병하는 질환, 예를 들면 퇴행성 질환 또는 파킨슨병 등의 예방 및 치료의 목적으로 유효하게 적용될 수 있다.
Through this, the composition according to the present invention can be effectively applied for the purpose of prevention and treatment of diseases, for example, degenerative diseases or Parkinson's disease, which are associated with a decrease in mitochondrial function.
도 1은 근육세포로 분화시킨 C2C12 세포에 각 시험물질을 처리한 후 유세포 분석기(flow cytometry)를 이용하여 미토콘드리아 양을 측정한 결과를 보여주는 그래프이다.
도 2는 미토콘드리아 막전위(mitochondria membrane potential) 측정 결과를 보여주는 그래프이다.
도 3은 인간 피부 섬유아세포에서 NAD+/NADH 비를 정량한 결과를 보여주는 그래프이다.
도 4는 자외선 조사에 의한 미토콘드리아 DNA 손상 정도를 측정한 결과를 보여주는 그래프이다.
도 5는 실시예 1 및 비교예 1,2 섭취군의 탈진 시까지의 트레드밀 운동 시간을 나타낸 그래프이다.1 is a graph showing the results of measuring mitochondria using flow cytometry after each test material was treated to C2C12 cells differentiated into muscle cells.
Figure 2 is a graph showing the results of mitochondria membrane potential (mitochondria membrane potential) measurement.
Figure 3 is a graph showing the results of quantifying the NAD + / NADH ratio in human skin fibroblasts.
Figure 4 is a graph showing the results of measuring the degree of mitochondrial DNA damage by ultraviolet irradiation.
5 is a graph showing the treadmill exercise time until exhaustion of the intake groups of Example 1 and Comparative Examples 1,2.
본 발명은 인삼 열매 추출물을 유효성분으로 함유하는 미토콘드리아 활성화를 위한 조성물에 관한 것이다.The present invention relates to a composition for mitochondrial activation containing ginseng fruit extract as an active ingredient.
본 발명의 일 실시예에 따른 조성물에 포함되는 인삼 열매 추출물은 인삼 열매에서 종자를 제거하여 인삼 열매의 과육과 과피를 포함하는 추출물일 수도 있고, 또한 인삼 열매의 과육만을 포함하는 추출물일 수도 있으며, 또한 인삼 열매의 과피만을 포함하는 추출물일 수도 있다.The ginseng fruit extract included in the composition according to an embodiment of the present invention may be an extract including the pulp and fruit of the ginseng fruit by removing the seed from the ginseng fruit, or may be an extract containing only the pulp of the ginseng fruit. It may also be an extract containing only the skin of the ginseng fruit.
상기 인삼 열매 추출물은 예를 들어 물 또는 저급 알코올, 예를 들어 메탄올, 에탄올 등으로 추출하여 제조된 것일 수 있으며, 상기 추출 방법에 한정되지 않고, 통상적으로 식품 분야에서 사용되는 천연물의 추출 방법을 이용하여 수득될 수 있음은 물론이다.The ginseng fruit extract may be prepared by extracting with water or lower alcohol, for example methanol, ethanol, for example, is not limited to the extraction method, using the extraction method of natural products commonly used in the food field Of course, it can be obtained by.
본 발명의 일 실시예에 따른 조성물에 포함되는 인삼 열매 추출물, 인삼 열매의 과피 추출물, 인삼 열매의 과육 추출물은 미토콘드리아 DNA의 복제수(copy number)를 증가시켰으며, 피로 회복을 촉진시켰다. 또한 미토콘드리아 막전위를 감소시켰고, NAD+/NADH 비를 증가시켰으며 자외선 조사에 의한 미토콘드리아 DNA 손상을 저해하였다.Ginseng fruit extract, ginseng fruit rind extract, ginseng fruit pulp extract included in the composition according to an embodiment of the present invention increased the copy number of mitochondrial DNA and promoted fatigue recovery. It also reduced mitochondrial membrane potential, increased NAD + / NADH ratio, and inhibited mitochondrial DNA damage by UV irradiation.
본 발명의 일 실시예에서 조성물에 포함되는 인삼 열매 추출물, 인삼 열매의과피 추출물, 인삼 열매의 과육 추출물은 미토콘드리아의 활성 저하와 관련된 각종 퇴행성 질환, 뇌 질환, 신경 질환, 심장 질환, 간 질환, 신장 질환, 췌장 질환 또는 근육 질환의 예방 또는 치료용 조성물일 수 있다. 또한 본 발명의 조성물은 피로 회복용 조성물일 수 있다.In one embodiment of the present invention, the ginseng fruit extract, the ginseng fruit extract, and the ginseng fruit extract are included in the composition, various degenerative diseases, brain diseases, neurological diseases, heart diseases, liver diseases, kidneys associated with decreased mitochondrial activity. It may be a composition for preventing or treating diseases, pancreatic diseases or muscle diseases. In addition, the composition of the present invention may be a composition for fatigue recovery.
상기 퇴행성 질환은 특별히 제한되지 않으나, 예를 들어 퇴행성관절염, 류마티스성 관절염 또는 골성관절염 일 수 있다. 이러한 질환들은 미토콘드리아의 활성이 저하되는 경우, 연골세포에서 COX-2(Cyclooxygenase-2)와 같은 염증 관련 인자 발현의 증가를 통해 발병할 수 있다.The degenerative disease is not particularly limited, but may be, for example, degenerative arthritis, rheumatoid arthritis or osteoarthritis. These diseases may be caused by increased expression of inflammation-related factors such as COX-2 (Cyclooxygenase-2) in chondrocytes when mitochondrial activity is reduced.
상기 뇌 질환은 특별히 제한되지 않으나, 예를 들어 파킨슨병, 발달지연, 신경정신장애, 자폐증, 정신지체, 발작 또는 중풍일 수 있다. 이러한 질환들은 미토콘드리아의 활성이 저하에 의해 발생한 활성산소가 뇌질환 특히, 치매의 주 원인인 아밀로이드(amyloid)의 생성을 증가시키고, 체내 축적되면서 발병할 수 있다.The brain disease is not particularly limited, but may be, for example, Parkinson's disease, developmental delay, neuropsychiatric disorder, autism, mental retardation, seizure or stroke. These diseases can occur when free radicals caused by the deactivation of mitochondria increase the production of amyloid, a major cause of brain disease, particularly dementia, and accumulate in the body.
상기 신경 질환은 특별히 제한되지 않으나, 예를 들어 안검하수, 시신경위축, 사시, 망막색소변성증, 실명, 청력손실, 눈근육마비, 반사작용 저하, 실신, 신경 통증 또는 자율신경실조증일 수 있다. The neurological disease is not particularly limited, but may be, for example, ptosis, optic nerve atrophy, strabismus, retinal pigmentosa, blindness, hearing loss, eye muscle palsy, decreased reflex, fainting, nerve pain or autonomic ataxia.
상기 심장 질환은 특별히 제한되지 않으나, 예를 들어 심장마비 또는 심장근육병증일 수 있다. 이러한 질환들은 미토콘드리아의 활성이 저하되는 경우, 심장 기능에 문제를 일으킬 수 있는 칼슘 이온의 과부하, 또는 산화 스트레스를 통해 발병할 수 있다.The heart disease is not particularly limited, but may be, for example, heart attack or cardiomyopathy. These diseases can be caused by overloading of calcium ions or oxidative stress, which can lead to heart function problems when mitochondrial activity is reduced.
상기 간 질환은 특별히 제한되지 않으나, 예를 들어 저혈당증 또는 간부전일 수 있다.The liver disease is not particularly limited, but may be, for example, hypoglycemia or liver failure.
상기 신장 질환은 특별히 제한되지 않으나, 예를 들어 신세뇨관산증일 수 있다. 이러한 질환들은 미토콘드리아의 활성이 저하되는 경우, 미토콘드리아의 호흡 시스템이 손상을 받으면 산화 스트레스가 증가하면서 발병의 원인이 될 수 있다.The kidney disease is not particularly limited, but may be, for example, renal tubuloacidosis. These diseases can be caused when the mitochondrial activity is reduced, if the mitochondrial respiratory system is damaged, the oxidative stress increases.
상기 췌장 질환은 특별히 제한되지 않으나, 예를 들어 췌장외분비기능부족증 또는 부갑상선부족증일 수 있다.The pancreatic disease is not particularly limited, but may be, for example, pancreatic exocrine dysfunction or parathyroid deficiency.
상기 근육 질환은 특별히 제한되지 않으나, 예를 들어 과민성 장 증후군, 근육통, 근이영양증, 위식도역류질환, 저혈압, 경련, 운동장애, 변비 또는 설사일 수 있다. 이러한 질환들은 미토콘드리아의 활성이 저하되는 경우, 체내 에너지원인 ATP의 생성이 억제되면서 근육의 정상적인 움직임에 영향을 주어 발병할 수 있다.The muscle disease is not particularly limited, but may be, for example, irritable bowel syndrome, myalgia, muscular dystrophy, gastroesophageal reflux disease, hypotension, convulsions, dyskinesia, constipation or diarrhea. These diseases may occur when mitochondrial activity decreases, affecting the normal movement of muscles while inhibiting the production of ATP, which is an energy source in the body.
본 발명에 의한 미토콘드리아 활성화를 위한 조성물은 그 제형이 특별히 제한되지 않으나, 예를 들어 약학 조성물 또는 건강식품 조성물일 수 있다.The composition for mitochondrial activation according to the present invention is not particularly limited in its formulation, but may be, for example, a pharmaceutical composition or a health food composition.
본 발명에 의한 조성물이 약학 조성물인 경우 통상의 방법에 따라 경구용 제형, 외용제, 좌제 및 멸균 주사용액 등의 형태로 제형화하여 사용될 수 있다.When the composition according to the present invention is a pharmaceutical composition, it can be used by formulating in the form of oral dosage form, external preparation, suppository, and sterile injectable solution according to a conventional method.
또한, 필요에 따라서 상기 조성물에 하기의 첨가제의 1종 또는 2종 이상을 첨가 배합할 수 있다. 상기 첨가제로는, 예를 들어 그레이프프루트, 사과, 오렌지, 레몬, 파인애플, 바나나, 배 등의 각종 과즙(농축 과즙, 분말 과즙 등이어도 좋다); 비타민류(팔미트산 레티놀, 리보플라빈, 피리독신, 시아노코발아민(cyanocobalamine), 아스코르빈산 나트륨, 니코틴산 아미드, 판토텐산 칼슘, 엽산, 비오틴, 콜레칼시페롤(cholecalciferol), 중주석산 콜린, 토코페롤 또는 β-카로틴 등의 수용성 및 지용성 비타민류); 향미료(레몬플레이버, 오렌지플레이버, 딸리플레이버, 그레이프프루트플레이버 또는 바닐라 에센스 등); 아미노산, 핵산 및 그들의 염류(글루탐산, 글루탐산나트륨, 글리신, 알라닌, 아스파라긴산, 아스파라긴산 나트륨, 이노신산 등); 식물 섬유(폴리덱스트로오스, 펙틴, 크산탄 고무, 글루코만난 또는 알긴산 등); 또는 미네랄류(염화나트륨, 초산나트륨, 황산마그네슘, 염화칼륨, 염화마그네슘, 탄산마그네슘, 염화칼슘, 인산 2칼륨, 인산 1나트륨, 글리세로인산칼슘, 구연산제1철나트륨, 구연산철암모늄, 구연산철, 황산망간, 황산구리, 요오드화나트륨, 솔빈산칼륨, 아연, 망간, 구리, 요오드 또는 코발트 등) 등이 포함될 수 있다.Moreover, 1 type, or 2 or more types of the following additives can be added and mix | blended with the said composition as needed. As said additive, For example, various fruit juices, such as grapefruit, an apple, an orange, a lemon, a pineapple, a banana, a pear, may be concentrated juice, powder juice, etc .; Vitamins (remicol retinol, riboflavin, pyridoxine, cyanocobalamine, sodium ascorbate, nicotinic acid amide, calcium pantothenate, folic acid, biotin, cholecalciferol, cholinergic tartaric acid, choline, tocopherol or β Water-soluble and fat-soluble vitamins such as carotene); Flavors (lemon flavors, orange flavors, tali flavors, grapefruit flavors or vanilla essences, etc.); Amino acids, nucleic acids and salts thereof (glutamic acid, sodium glutamate, glycine, alanine, aspartic acid, sodium aspartate, inosinic acid, etc.); Plant fibers (polydextrose, pectin, xanthan gum, glucomannan or alginic acid, etc.); Or minerals (sodium chloride, sodium acetate, magnesium sulfate, potassium chloride, magnesium chloride, magnesium carbonate, calcium chloride, dipotassium phosphate, monosodium phosphate, calcium glycophosphate, ferrous citrate, ammonium ferric citrate, iron citrate, manganese sulfate, Copper sulfate, sodium iodide, potassium sorbate, zinc, manganese, copper, iodine or cobalt, and the like.
상기 조성물에는 방부제, 안정화제, 수화제 또는 유화 촉진제, 삼투압 조절을 위한 염 및/또는 완충제 등의 약제학적 보조제 및 기타 치료적으로 유용한 물질을 추가로 함유할 수 있으며, 통상적인 방법에 따라 다양한 경구용 또는 비경구용 투여 형태로 제형화할 수 있다.The composition may further contain pharmaceutical adjuvants such as preservatives, stabilizers, emulsifiers or emulsifiers, salts and / or buffers for the control of osmotic pressure and other therapeutically useful substances, and can be used in various oral forms according to conventional methods. Or in parenteral dosage forms.
경구용 제형으로는 예를 들면, 정제, 환제, 경질 및 연질 캅셀제, 액제, 현탁제, 유화제, 시럽제, 과립제 등이 있는데, 이들 제형은 유효성분 이외에 희석제(예: 락토오스, 덱스트로오스, 수크로오스, 만니톨, 솔비톨, 셀룰로오스 및 글리신), 활택제(예: 실리카, 탈크, 스테아르산 및 그의 마그네슘 또는 칼슘염 및 폴리에틸렌 글리콜)를 함유하고 있다. 정제는 마그네슘 알루미늄 실리케이트, 전분 페이스트, 젤라틴, 트라가칸스, 메틸셀룰로오스, 나트륨 카복시메틸셀룰로오스 및 폴리비닐피롤리딘과 같은 결합제를 더 함유할 수 있으며, 경우에 따라 전분, 한천, 알긴산 또는 그의 나트륨 염과 같은 붕해제, 흡수제, 착색제, 향미제, 및 감미제 등의 약제학적 첨가제를 함유할 수 있다. 정제는 통상적인 혼합, 과립화 또는 코팅 방법에 의해 제조될 수 있다. 또한, 비경구 투여용 제형의 대표적인 것은 주사용 제형으로 등장성 수용액 또는 현탁액이 바람직하다. Oral formulations include, for example, tablets, pills, hard and soft capsules, solutions, suspensions, emulsifiers, syrups, granules, etc. These formulations may contain diluents (e.g. lactose, dextrose, sucrose, Mannitol, sorbitol, cellulose and glycine), lubricants such as silica, talc, stearic acid and its magnesium or calcium salts and polyethylene glycols. Tablets may further contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidine, optionally starch, agar, alginic acid or its sodium salt Pharmaceutical additives such as disintegrants, absorbents, colorants, flavors, and sweeteners. Tablets may be prepared by conventional mixing, granulating or coating methods. Also representative of formulations for parenteral administration are injectable formulations, preferably aqueous isotonic solutions or suspensions.
또한 본 발명에 의한 조성물이 건강식품 조성물이 경우에는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제 또는 건강 기능성 식품류 등으로 제형화될 수 있다. 본 발명에서 사용하는 인삼 열매는 독성 및 부작용이 거의 없으므로 예방 목적으로 장기간 복용 시에도 안심하고 사용할 수 있다.In addition, when the composition according to the present invention is a health food composition, for example, it can be formulated into various foods, beverages, gums, teas, vitamin complexes or health functional foods. The ginseng fruit used in the present invention has little toxicity and side effects, so it can be used safely even when taken for a long time for the purpose of prevention.
본 발명의 건강식품 조성물은 지시된 비율로 필수 성분으로서 인삼 열매 추출물을 함유하는 외에는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토오스, 수크로오스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 1∼20 g, 바람직하게는 약 5∼12 g이다.The health food composition of the present invention is not particularly limited to other ingredients except the ginseng fruit extract as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 조성물은 여러가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 향미증진제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올 또는 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 조성물들은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 조성물 총 중량에 대하여 0∼20 중량%의 범위에서 선택되는 것이 일반적이다.In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and flavor enhancers, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloids. Thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols or carbonation agents used in carbonated beverages; The compositions of the present invention may also contain pulp for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical but is usually chosen in the range of 0 to 20% by weight, based on the total weight of the composition of the present invention.
상기 인삼 열매 추출물, 인삼 열매의 과피 추출물, 인삼 열매의 과육 추출물의 투여량은 당업자의 수준 내의 범위에서 한정될 수 있으며, 본 발명에 따른 조성물의 1일 투여 용량은 투여하고자 하는 대상의 미만 진행 정도, 발병 시기, 연령, 건강상태, 합병증 등의 다양한 요인에 따라 달라지지만, 성인을 기준으로 할 때 일반적으로는 상기 언급된 중량비로 조합된 조성물 1 내지 500 mg/kg, 바람직하게는 30 내지 200 mg/kg을 1일 1 내지 2회 분할하여 투여할 수 있으며, 상기 투여량은 어떠한 방법으로도 본 발명의 범위를 한정하는 것이 아니다.Dosage of the ginseng fruit extract, ginseng fruit rind extract, ginseng fruit pulp extract may be limited within the level of those skilled in the art, the daily dosage of the composition according to the present invention is less than the progress of the subject to be administered Depends on a variety of factors, such as onset, age, health status, complications, etc., but on the basis of an adult, generally from 1 to 500 mg / kg, preferably 30 to 200 mg / kg may be administered by dividing 1 to 2 times a day, and the dosage does not limit the scope of the present invention in any way.
상기 인삼 열매 추출물, 인삼 열매의 과피 추출물, 인삼 열매의 과육 추출물 의 함량은 특별히 제한되지 않으나, 조성물 총 중량에 대하여 10∼90 중량% 범위로 함유되는 것이 바람직하다. 이는 정제 및 연질캡슐 제조시, 분말 및 기능성 성분의 함량이 10∼60%, 하드캡슐의 제조 시, 분말 및 기능성 성분의 함량이 10∼90%일 수 있는 점을 고려하여, 인삼 열매 추출물을 10∼90%로 함유하는 건강식품 조성물 또는 약학 조성물을 제공할 수 있다.
The content of the ginseng fruit extract, the skin extract of ginseng fruit, the flesh extract of ginseng fruit is not particularly limited, but is preferably contained in the range of 10 to 90% by weight based on the total weight of the composition. The ginseng fruit extract may be prepared in consideration of the fact that the content of the powder and the functional ingredient may be 10-60% in the manufacture of tablets and soft capsules, and the content of the powder and the functional ingredient may be 10-90% in the manufacture of hard capsules. A health food composition or a pharmaceutical composition containing at -90% can be provided.
이하, 본 발명의 내용을 실시예 및 시험예를 통하여 보다 구체적으로 설명한다. 이들 실시예는 본 발명의 내용을 이해하기 위해 제시되는 것일 뿐 본 발명의 권리범위가 이들 실시예로 한정되는 것은 아니고, 당업계에서 통상적으로 주지된 변형, 치환 및 삽입 등을 수행할 수 있으며, 이에 대한 것도 본 발명의 범위에 포함된다.
Hereinafter, the present invention will be described more specifically with reference to examples and test examples. These examples are provided only for understanding the contents of the present invention, and the scope of the present invention is not limited to these examples, and modifications, substitutions, and insertions commonly known in the art may be performed. This is also included in the scope of the present invention.
[실시예 1] 인삼 열매 추출물 제조Example 1 Preparation of Ginseng Fruit Extract
1) 인삼 열매 전처리: 생(生)인삼 열매를 수확하여 종자를 분리하여 제거한 후 인삼 열매의 과육과 과피를 일광건조 또는 열풍건조를 통하여 인삼 열매 건조원료를 제조하였다.1) Ginseng fruit pretreatment: Raw ginseng fruit was harvested, seed was separated and removed, and then the ginseng fruit dried raw material was prepared by sun drying or hot air drying.
2) 인삼 열매 추출물 제조: 인삼 열매 건조물 1 kg에 물 3 L를 가하여 환류 추출한 다음 여과한 후 40∼45℃에서 감압농축하여 인삼 열매 추출물 300 g을 얻었다.
2) Preparation of ginseng fruit extract: 3 g of water was added to 1 kg of dried ginseng fruit extract to extract reflux, and then filtered and concentrated under reduced pressure at 40 to 45 ° C. to obtain 300 g of ginseng fruit extract.
[실시예 2] 인삼 열매의 과피 추출물을 제조Example 2 Preparation of Skin Extract of Ginseng Fruit
인삼 열매에서 과피만을 분리하여, 상기 실시예 1의 인삼 열매 추출물의 제조 방법과 실질적으로 동일한 방법으로 제조하여 인삼 열매의 과피 추출물을 수득하였다.
Only peeled skin from the ginseng fruit, was prepared in substantially the same manner as the production method of the ginseng fruit extract of Example 1 to obtain a skin extract of ginseng fruit.
[실시예 3] 인삼 열매의 과육 추출물을 제조Example 3 Preparation of a pulp extract of ginseng fruit
인삼 열매에서 과피만을 분리하여, 상기 실시예 1의 인삼 열매 추출물의 제조 방법과 실질적으로 동일한 방법으로 제조하여 인삼 열매의 과피 추출물을 수득하였다.
Only peeled skin from the ginseng fruit, was prepared in substantially the same manner as the production method of the ginseng fruit extract of Example 1 to obtain a skin extract of ginseng fruit.
[비교예 1 및 2] 인삼근 및 홍삼 추출물[Comparative Examples 1 and 2] Ginseng Root and Red Ginseng Extract
인삼근과 홍삼 각 1 kg에 물 3 L를 가하여 환류 추출한 다음 여과한 후 40∼45℃에서 감압농축하여 인삼근 및 홍삼 추출물을 제조하였다.
3 g of water was added to each 1 kg of ginseng root and red ginseng to extract reflux, and then filtered.
[시험예 1] 인삼 열매 추출물의 성분비교Test Example 1 Comparison of Ingredients of Ginseng Fruit Extract
<인삼 열매와 인삼근의 진세노사이드(인삼사포닌) 성분분석><Ginsenoside (Ginseng Saponin) Analysis of Ginseng Fruit and Ginseng Root>
실시예 1 및 비교예 1에서 각각 인삼 열매와 인삼근 추출물을 제조한 다음 이들 추출물에 에테르(ether)를 처리하여 지용성 성분을 제거한 후 부탄올(BuOH)로 조사포닌을 추출, 농축하여 HPLC를 통한 진세노사이드 성분분석을 실시하였으며, 그 결과를 하기 표 1에 나타내었다.In Example 1 and Comparative Example 1, respectively, ginseng fruit and ginseng root extract were prepared, and then, the extracts were treated with ether to remove fat-soluble components, followed by extracting and concentrating ginsponin with butanol (BuOH). Cenoside component analysis was performed, and the results are shown in Table 1 below.
실시예 1에서 제조한 인삼 열매 추출물은 조사포닌 함량에 있어서 비교예 1에서 제조한 인삼근 추출물의 약 2배 함량을 가지고 있었으며, 진세노사이드를 PD(Protopanaxadiol)계-"진세노사이드 Rb1, Rb2, Rc 및 Rd" 및 PT(Protopanaxatriol)계-"진세노사이드 Re, Rg1 및 Rg2"의 비율로 구분하였을 때 각각 0.73과 3.23으로 그 조성에 있어서 인삼 열매와 인삼근은 뚜렷한 차이 및 특징을 나타내었다.
The ginseng fruit extract prepared in Example 1 had about twice the content of the ginseng root extract prepared in Comparative Example 1 in the content of irradiated phonynin, and ginsenosides were PD (Protopanaxadiol)-"ginsenoside Rb1, Rb2. And Rc and Rd "and PT (Protopanaxatriol)-" Ginsenoside Re, Rg1 and Rg2 "ratios were 0.73 and 3.23, respectively. .
<인삼 열매 추출물의 미네랄 성분분석>Mineral Analysis of Ginseng Fruit Extract
실시예 1에서 제조한 인삼 열매 추출물이 인삼과는 다른 '과실'로서의 특징을 가짐을 구분하기 위하여 비타민을 비롯한 미네랄 성분분석을 실시하였으며, 그 결과를 하기 표 2에 나타내었다.In order to distinguish that the ginseng fruit extract prepared in Example 1 has the characteristics of 'fruit' different from ginseng, mineral components including vitamins were analyzed, and the results are shown in Table 2 below.
이상과 같이 본 발명에서 사용하는 인삼 열매의 성분적 특성은 인삼근 보다 많은 인삼사포닌을 함유함과 동시에 사포닌 조성의 성질이 정반대이고, 또한 인삼근과 달리 열매로서 비타민과 미네랄 16 종의 함량이 풍부함을 확인할 수 있었다.
As described above, the ginseng fruit used in the present invention contains more ginseng saponin than the ginseng root, and at the same time, the composition of the saponin is opposite to that of the ginseng root. Could confirm.
이하, 본 발명에서는 in vitro 실험을 통해서 본 발명에 의한 인삼 열매 추출물이 미토콘드리아 생성에 미치는 영향을 분석하였다.
Hereinafter, in the present invention, the effect of ginseng fruit extract according to the present invention on the mitochondria production was analyzed through in vitro experiments.
[시험예 2] 미토콘드리아 수에 미치는 영향Test Example 2 Effect on the Number of Mitochondria
(1) (One) C2C12C2C12 세포의 배양 및 분화 Culture and Differentiation of Cells
C2C12는 생쥐 유래 세포이며, ATCC에서 구입하였다. C2C12 세포를 10 % 우혈청(fetal bovine serum), 1% 페니실린/스트렙토마이신을 포함한 포도당 4.5 g/L의 DMEM(Dulbecco modified eagle's medium)에서 배양하였다. 배양 접시 내의 세포 밀도가 95∼100%에 이르게 되면, 근육세포로 분화할 수 있도록 2% 말 혈청(horse serum), 1% 페니실린/스트렙토마이신을 포함한 포도당 4.5 g/L의 DMEM으로 배양액을 교환하여 약 5일 정도 분화시켰다.
C2C12 is a mouse derived cell and was purchased from ATCC. C2C12 cells were cultured in Dulbecco modified eagle's medium (DMEM) of 4.5 g / L glucose with 10% fetal bovine serum, 1% penicillin / streptomycin. When the cell density in the culture plate reaches 95-100%, the culture medium is exchanged with 4.5 g / L DMEM containing 2% horse serum and 1% penicillin / streptomycin to differentiate into muscle cells. It erupted for about 5 days.
(2) (2) 미토콘드리아수Mitochondria 측정 Measure
위에서 근육세포로 분화시킨 C2C12 세포에 양성대조군인 레스버라트롤(resveratrol) 50 μM, 실시예 1의 인삼 열매 추출물, 실시예 2의 인삼 열매의 과피 추출물, 및 실시예 3의 인삼 열매의 과육 추출물 각 100 mg/ml 과 진세노사이드 Rg, Rb 및 Re 각 50 μM을 24시간 동안 처리하였다. 다음날 PBS로 3회 세척하고, 미토콘드리아의 양을 측정하기 위하여 37℃에서 30 분간 25 nM의 미토트레커 레드(mitotracker Red; Molecular Probes, Invitrogen)으로 염색한 후 유세포 분석기(flow cytometry)를 이용하여 측정하였으며, 그 결과는 도 1에 나타내었다.50 μM of resveratrol, a positive control group, ginseng fruit extract of Example 1, rind extract of ginseng fruit of Example 2, and pulp extract of ginseng fruit of Example 3 on C2C12 cells differentiated into
도 1의 결과에서, 인삼 열매 추출물을 처리한 군에서 미토콘드리아 수가 유의적으로 증가하였으며, 특히 인삼 열매의 과육 추출물을 처리한 군은 진세노사이드 Rg, Rb 및 Re를 처리한 군에 비해 미토콘드리아 수가 현저히 증가하였고, 양성대조군인 레스베라트롤과 동등한 수준을 유지하였다.
In the results of Figure 1, the number of mitochondria increased significantly in the group treated with ginseng fruit extract, especially the group treated with the pulp extract of ginseng fruit mitochondria number significantly compared to the group treated with ginsenoside Rg, Rb and Re It increased, and remained at the same level as the positive control resveratrol.
[시험예 3] 미토콘드리아 막 전위( mitochondria membrane potential )에 미치는 영향[Test Example 3] mitochondria membrane potential ( mitochondria membrane potential )
인간 피부 섬유아세포(Human dermal fibroblast cell)를 형광측정용 96웰 블랙 플레이트에 웰당 1.0×105개로 분주하고 페니실린/스트렙토마이신이 첨가된 DMEM(FBS 10%) 배지를 사용하여 37℃, 5% CO2 조건에서 1일간 배양한 후 각 시료(트롤록스 1 및 10 ppm, 실시예 1의 인삼 열매 추출물 0.1, 1 및 10 ppm)를 처리하였다. 시료 처리에 사용된 배지로 페니실린/스트렙토마이신이 첨가된 DMEM(FBS 무첨가)을 사용하고 37℃, 5% CO2 조건에서 1일간 배양하였다. 시험군에 H2O2를 500 μM 농도로 90분 처리한 후 세척하였다. 세척용으로 1x PBS 완충 식염수(Sigma Co.)를 사용하였다. 세척 후, 시험시료를 넣고 72시간 배양한 후 PBS로 세척하여 남아 있는 배지를 제거하고 적당량의 PBS를 가한 후 UVA(5 J/㎡)와 UVB(30 mJ/㎠)를 각각 처리하고 시료가 함유된 배지를 넣고 37℃, 5% CO2 조건에서 24시간 배양하였다. 배양 후 HCSS로 배지를 제거한 후 10 ㎍/ml로 제조된 JC-1을 넣고 37℃, 5% CO2 조건에서 20분간 배양하였다. 배양 후 HCSS로 세척하고 적당량의 HCSS를 가하여 형광플레이트 리더(Ex=485 nm, Em=530 nm green/Ex=530 nm, Em=590 nm red)로 형광 강도를 측정하여 막전위를 비교하였으며, 그 결과를 도 2에 나타내었다.Human dermal fibroblast cells were dispensed at 1.0 × 10 5 per well into a 96-well black plate for fluorescence measurement and 37 ° C., 5% CO using DMEM (
도 2의 결과에서, 인삼 열매 추출물을 처리한 군에서 H2O2에 의한 미토콘드리아 막전위 감소를 20∼35% 이상 회복하는 것을 확인하였다. 이는 세포의 활성화를 의미하며, ATP 생성 잠재력이 증가되는 것을 의미한다.
In the results of Figure 2, it was confirmed that the mitochondrial membrane potential reduction by H 2 O 2 in the group treated with ginseng fruit extract recovers 20 to 35% or more. This means activation of the cell, which means that the potential for ATP production is increased.
[시험예 4] NAD+/NADH 비(ratio)에 미치는 영향Test Example 4 Effect on NAD + / NADH ratio
인간 피부 섬유아세포를 형광측정용 24웰 플레이트에 각 웰당 5.0x105 개로 분주하고 페니실린/스트렙토마이신이 첨가된 DMEM(FBS 10% 첨가) 배지를 사용하여 37℃, 5% CO2 조건에서 1일간 배양한 후 각 시료(인삼 열매 추출물 1, 3, 10 및 100 ppm)를 처리하였다. 시료 처리에 사용된 배지로 페니실린/스트렙토마이신이 첨가된 DMEM(FBS 무첨가)을 사용하고 37℃, 5% CO2 조건에서 1일간 배양하였다. 세척용으로 1xPBS 완충 식염수(Sigma Co.)을 사용하였다. 세척 후, 시험시료를 넣고 72시간 배양한 후 PBS로 세척하여 남아있는 배지를 제거하고 NAD+/NADH 비 분석 키트(ab65348, abcam)를 이용하여 정량하였으며, 그 결과를 도 3에 나타내었다. Human dermal fibroblasts were dispensed at 5.0 × 10 5 per well in a 24-well plate for fluorescence measurement and 37 ° C., 5% CO 2 using DMEM (10% FBS) medium supplemented with penicillin / streptomycin. After culturing for 1 day under the conditions, each sample (
도 3의 결과에서, 인삼 열매 추출물을 처리한 군에서 섬유아세포의 NAD+/NADH 비가 150-200% 이상 증가되는 것을 확인하였다. 이러한 NAD+/NADH 비의 증가는 이에 의한 SIRT1 등의 탈아세틸화효소의 활성을 증가시킬 수 있다.
In the results of Figure 3, it was confirmed that the NAD + / NADH ratio of fibroblasts in the group treated with ginseng fruit extract increased by more than 150-200%. This increase in NAD + / NADH ratio can thereby increase the activity of deacetylase, such as SIRT1.
[시험예 5] 자외선 조사에 의해 유도되는 미토콘드리아 DNA 변이 저해 효과Test Example 5 Inhibition of Mitochondrial DNA Mutation Induced by UV Irradiation
1) NHDF 세포의 배양 및 처리1) Culture and Treatment of NHDF Cells
실험에 사용한 세포주는 사람유래의 피부 진피 조직 세포로, ATCC에서 구입하였다. NHDF(Normal Human Dermal Fibroblast) 세포를 10% 우혈청(FBS: fetal bovine serum), 1% 페니실린/스트렙토마이신을 포함한 포도당 4.5 g/L의 DMEM에서 배양하였다. 6웰 플레이트에 각 웰당 5.0×104개로 분주하여 37℃, 5% CO2 조건에서 하루 동안 배양시킨 후, 1% 우혈청이 포함된 DMEM으로 배지를 교환하여 4시간 동안 두었다. 이 후 인삼 열매 추출물을 100 ppm의 농도로 세포에 하루 동안 처리한 다음 PBS로 세척하여 남아있는 배지를 제거하고 1x PBS를 1 ml씩 분주하여 UVB(50 mJ/㎠)를 각각의 실험조건의 세기로 처리하고 하루 배양 후 실험에 사용하였다.The cell lines used in the experiments were human dermal dermal tissue cells, which were purchased from ATCC. Normal Human Dermal Fibroblast (NHDF) cells were cultured in 4.5 g / L DMEM containing 10% fetal bovine serum (FBS), 1% penicillin / streptomycin. After dispensing 5.0 × 10 4 per well into 6-well plates and incubating for one day at 37 ° C. and 5% CO 2 conditions, medium was exchanged with DMEM containing 1% bovine serum and left for 4 hours. After that, the ginseng fruit extract was treated with cells at a concentration of 100 ppm for one day, washed with PBS to remove the remaining medium, and 1 ml of 1 × PBS was dispensed to obtain UVB (50 mJ / ㎠) for each experimental condition. It was treated with and used for the experiment after one day incubation.
2) 자외선 조사에 의한 미토콘드리아 DNA 손상 회복2) Restoration of mitochondrial DNA damage by UV irradiation
자외선을 조사한 세포를 1x PBS로 세척한 다음 FastPureTM DNA 키트(Takara)를 이용하여 게놈 DNA를 추출하였다. 추출한 DNA 5 ng을 iQTM SYBR® Green Supermix (Bio-Rad) 및 하기 표 3에 기재된 프라이머를 이용하여 정량적 실시간 PCR을 수행하였다.Ultraviolet irradiated cells were washed with 1 × PBS and genomic DNA was extracted using FastPure ™ DNA kit (Takara). The extracted DNA 5 ng iQ TM Quantitative real-time PCR was performed using SYBR® Green Supermix (Bio-Rad) and the primers described in Table 3 below.
PCR 증폭은 95℃, 3분간 초기 변성 후 95℃에서 30초간 변성, 60℃에서 30초간 어닐링 및 72℃에서 30초간 확장하는 사이클을 30회 반복한 후 72℃에서 10분간 확장시키는 조건으로 하여 CT법(comparative cycle threshold method)을 통해 결과를 얻었으며, 그 결과를 도 4에 나타내었다.PCR amplification was performed under the condition that the cells were denatured at 95 ° C for 3 minutes, denatured at 95 ° C for 30 seconds, annealed at 60 ° C for 30 seconds, and extended at 72 ° C for 30 seconds, and then expanded at 72 ° C for 10 minutes. The result was obtained through a method (comparative cycle threshold method), and the results are shown in FIG. 4.
도 4의 결과에서, 자외선 조사에 의해 53% 증가하였던 미토콘드리아 3,895 bp 결실 손상이 인삼 열매 추출물에 의해 12% 감소하였음을 확인하였다.
In the results of Figure 4, it was confirmed that the mitochondrial 3,895 bp deletion damage was increased by 53% by ultraviolet irradiation was reduced by 12% by the ginseng fruit extract.
[시험예 5] 근력 측정Test Example 5 Strength Measurement
수컷 5주령 래트(rat: Sprague-Dawley) 32마리를 (주)중앙실험동물로부터 분양받아 고형배합사료((주) 삼양유지 사료)로 1주일간 예비사육한 후 무작위로 8 마리씩 4 군(시험물질을 처리하지 않은 대조군, 양성대조군인 글루타민 섭취군, 홍삼 추출물 및 인삼 열매 추출물 섭취군)으로 나누고 물과 사료는 자유롭게 섭취하도록 공급하였다.32 male 5-week-old rats (rat: Sprague-Dawley) were fed from a central laboratory animal and pre-bred for 1 week with solid blended feed (Samyang oil feed). Untreated control group, positive control glutamine intake group, red ginseng extract and ginseng fruit extract intake group) and water and feed were fed freely.
동물 사육실의 환경은 온도 23±1℃, 습도 50±5, 12시간 간격으로 낮과 밤의 사이클(12-hour light-dark cycle)을 유지하였으며, 식이 섭취량과 체중 증가량은 1주일에 1회 일정한 시간에 측정하였다. 실험에 이용된 식이는 AIN-93G를 기준으로 하였으며, 글루타민, 비교예 2의 홍삼 추출물 및 실시예 1의 인삼 열매 추출물을 각각 사료 1 ㎏당 30 g(총 식이 중량의 3%)씩 첨가하였다. 식이의 총 중량은 전분 및 단백질량에서 조정하였으며, 기타 실험식이의 자세한 사항은 표 4에 제시한 바와 같다. 표 4는 AIN-93에 의한 동물실험 식이 조성을 나타낸 것이다.The environment of the animal feeding room maintained a 12-hour light-dark cycle at a temperature of 23 ± 1 ° C, a humidity of 50 ± 5 and a 12 hour interval, and the dietary intake and weight gain were constant once a week. Measured at time. The diet used in the experiment was based on AIN-93G, and glutamine, red ginseng extract of Comparative Example 2 and ginseng fruit extract of Example 1 were added 30 g per kg of feed (3% of the total diet weight), respectively. The total weight of the diet was adjusted in the amount of starch and protein, and the details of other experimental diets are shown in Table 4. Table 4 shows the animal test diet composition by AIN-93.
모든 군은 1주일에 1회 근력 측정을 실시하였다. 측정방법은 Smith 등의 방법을 수정하여 실시하였으며, 그 결과를 도 4에 나타내었다. 최대근력 판정은 래트(rat)가 철봉(horizontal bar)을 놓는 시점으로 하였으며, 그때의 수치를 디지탈 인장 측정기(digital force gauge)를 통하여 나타내었다.All groups performed strength measurements once a week. The measurement method was carried out by modifying the method of Smith et al., The results are shown in FIG. Maximum strength was determined when the rat lays a horizontal bar, and the numerical value was then displayed through a digital force gauge.
도 5의 결과에서, 본 발명에 의한 인삼 열매 추출물은 시간 경과에 따라 유의적인 수준의 근력 향상을 보였고, 양성대조군인 글루타민과 비교하여도 동등 이상의 근력향상 효능을 보였다.
In the results of Figure 5, the ginseng fruit extract according to the present invention showed a significant level of strength improvement over time, even compared to the positive control glutamine showed an equal or greater strength improvement effect.
[제형예 1] 연질 캡슐의 제조Formulation Example 1 Preparation of Soft Capsule
실시예 1의 인삼 열매 추출물 80 mg, 비타민 E 9 mg, 비타민 C 9 mg, 팜유 2 mg, 식물성 경화유 8 mg, 황납 4 mg 및 레시틴 9 mg을 혼합하고, 통상의 방법에 따라 혼합하여 연질캡슐 충진액을 제조하였다. 1 캡슐당 400 ㎎씩 충진하여 연질캡슐을 제조하였다. 80 mg of ginseng fruit extract of Example 1, vitamin E 9 mg, vitamin C 9 mg,
상기와 별도로 젤라틴 66 중량부, 글리세린 24 중량부 및 솔비톨액 10 중량부의 비율로 연질캡슐시트를 제조하고 상기 충진액을 충진시켜 본 발명에 따른 조성물 400 mg이 함유된 연질캡슐을 제조하였다.
Apart from the above, a soft capsule sheet was prepared at a ratio of 66 parts by weight of gelatin, 24 parts by weight of glycerine, and 10 parts by weight of sorbitol solution and filled with the filler to prepare a soft capsule containing 400 mg of the composition according to the present invention.
[제형예 2] 정제의 제조Formulation Example 2 Preparation of Tablet
실시예 1의 인삼 열매 추출물 80 mg, 비타민 E 9 mg, 비타민 C 9 mg, 갈락토올리고당 200 ㎎, 유당 60 ㎎ 및 맥아당 140 ㎎을 혼합하고 유동층 건조기를 이용하여 과립한 후 당 에스테르(sugar ester) 6 ㎎을 첨가하였다. 이들 조성물 504 mg을 통상의 방법으로 타정하여 정제를 제조하였다.
Ginseng fruit extract of Example 1 80 mg, vitamin E 9 mg, vitamin C 9 mg, galactooligosaccharide 200 mg,
[제형예 3] 드링크제의 제조Formulation Example 3 Preparation of Drink
실시예 1의 인삼 열매 추출물 80 mg, 비타민 E 9 mg, 비타민 C 9 mg, 포도당 10 g, 구연산 0.6 g, 및 액상 올리고당 25 g을 혼합한 후 정제수 300 ㎖를 가하여 각 병에 200 ㎖씩 되게 충진하였다. 병에 충진한 후 130℃에서 4∼5 초간 살균하여 음료를 제조하였다.
80 mg of ginseng fruit extract of Example 1, 9 mg of vitamin E, 9 mg of vitamin C, 10 g of glucose, 0.6 g of citric acid, and 25 g of liquid oligosaccharide were mixed, and then 300 ml of purified water was added to each bottle to 200 ml. It was. After filling the bottle sterilized for 4 to 5 seconds at 130 ℃ to prepare a beverage.
[제형예 4] 과립의 제조Formulation Example 4 Preparation of Granules
실시예 1의 인삼 열매 추출물 80 mg, 비타민 E 9 mg, 비타민 C 9 mg, 무수결정 포도당 250 ㎎ 및 전분 550 ㎎을 혼합하고, 유동층 과립기를 사용하여 과립으로 성형한 후 포에 충진하여 제조하였다.
80 mg of ginseng fruit extract of Example 1, 9 mg of vitamin E, 9 mg of vitamin C, 250 mg of anhydrous glucose, and 550 mg of starch were mixed, molded into granules using a fluidized bed granulator, and then filled into fabrics.
<110> AMOREPACIFIC CORPORATION <120> Composition for activating mitochondria containing ginseng berry extracts <130> YPD-200912-0035 <160> 4 <170> KopatentIn 1.71 <210> 1 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> sense primer for 548-4443 nt in mitochondrial DNA <400> 1 gcttctggcc acagcactta 20 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> antisense primer for 548-4443 nt in mitochondrial DNA <400> 2 tagcgctgtg atgagtgtgc 20 <210> 3 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> sense primer for 83 bp conservative region of the mitochondrial DNA <400> 3 gatttgggta ccacccaagt attg 24 <210> 4 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> antisense primer for 83 bp conservative region of the mitochondrial DNA <400> 4 aatattcatg gtggctggca gta 23 <110> AMOREPACIFIC CORPORATION <120> Composition for activating mitochondria containing ginseng berry extracts <130> YPD-200912-0035 <160> 4 <170> KopatentIn 1.71 <210> 1 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> sense primer for 548-4443 nt in mitochondrial DNA <400> 1 gcttctggcc acagcactta 20 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> antisense primer for 548-4443 nt in mitochondrial DNA <400> 2 tagcgctgtg atgagtgtgc 20 <210> 3 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> sense primer for 83 bp conservative region of the mitochondrial DNA <400> 3 gatttgggta ccacccaagt attg 24 <210> 4 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> antisense primer for 83 bp conservative region of the mitochondrial DNA <400> 4 aatattcatg gtggctggca gta 23
Claims (14)
상기 조성물은 근력 강화용 조성물인 미토콘드리아 활성화를 위한 조성물. The method of claim 1,
The composition is a composition for mitochondrial activation that is a composition for strengthening muscle strength.
상기 조성물은 퇴행성 질환, 뇌 질환, 신경 질환, 심장 질환, 간 질환, 신장 질환, 췌장 질환 또는 근육 질환의 예방 또는 치료용 조성물인 미토콘드리아 활성화를 위한 조성물.The method of claim 1,
The composition is a composition for mitochondrial activation which is a composition for the prevention or treatment of degenerative diseases, brain diseases, neurological diseases, heart diseases, liver diseases, kidney diseases, pancreatic diseases or muscle diseases.
상기 조성물은 파킨슨병, 발달지연, 신경정신장애, 자폐증, 정신지체, 발작 또는 중풍의 예방 또는 치료용 조성물인 미토콘드리아 활성화를 위한 조성물.The method of claim 1,
The composition is a composition for mitochondrial activation that is a composition for the prevention or treatment of Parkinson's disease, developmental delay, neuropsychiatric disorders, autism, mental retardation, seizures or stroke.
상기 조성물은 안검하수, 시신경위축, 사시, 망막색소변성증, 실명, 청력손실, 눈근육마비, 반사작용 저하, 실신, 신경 통증 또는 자율신경실조증의 예방 또는 치료용 조성물인 미토콘드리아 활성화를 위한 조성물.The method of claim 1,
The composition is a composition for the prevention or treatment of ptosis, optic nerve atrophy, strabismus, retinal pigmentosa, blindness, hearing loss, eye muscle paralysis, reflexes, fainting, nerve pain or autonomic ataxia.
상기 조성물은 심장마비 또는 심장근육병증의 예방 또는 치료용 조성물인 미토콘드리아 활성화를 위한 조성물.The method of claim 1,
The composition is a composition for mitochondrial activation that is a composition for the prevention or treatment of heart attack or cardiomyopathy.
상기 조성물은 저혈당증 또는 간부전의 예방 또는 치료용 조성물인 미토콘드리아 활성화를 위한 조성물.The method of claim 1,
The composition is a composition for mitochondrial activation that is a composition for the prevention or treatment of hypoglycemia or liver failure.
상기 조성물은 신세뇨관산증의 예방 또는 치료용 조성물인 미토콘드리아 활성화를 위한 조성물.The method of claim 1,
The composition is a composition for mitochondrial activation that is a composition for the prevention or treatment of renal tubuloacidosis.
상기 조성물은 췌장외분비기능부족증 또는 부갑상선부족증의 예방 또는 치료용 조성물인 미토콘드리아 활성화를 위한 조성물.The method of claim 1,
The composition is a composition for mitochondrial activation that is a composition for the prevention or treatment of pancreatic exocrine dysfunction or parathyroid deficiency.
상기 조성물은 과민성 장 증후군, 근육통, 근이영양증, 위식도역류질환, 저혈압, 경련, 운동장애, 변비 또는 설사의 예방 또는 치료용 조성물인 미토콘드리아 활성화를 위한 조성물.The method of claim 1,
The composition is a composition for preventing or treating irritable bowel syndrome, myalgia, muscular dystrophy, gastroesophageal reflux disease, hypotension, spasms, dyskinesia, constipation or diarrhea.
상기 조성물은 피로 회복용인 미토콘드리아 활성화를 위한 조성물.The method of claim 1,
The composition is a composition for mitochondrial activation for fatigue recovery.
상기 조성물은 건강식품 조성물 또는 약학 조성물인 미토콘드리아 활성화를 위한 조성물. The method of claim 1,
The composition is a composition for mitochondria activation, which is a health food composition or a pharmaceutical composition.
상기 유효 성분은 조성물 전체 중량에 대하여 10∼90 중량%로 포함되는 미토콘드리아 활성화를 위한 조성물. The method of claim 1,
The active ingredient is a composition for mitochondrial activation comprises 10 to 90% by weight based on the total weight of the composition.
상기 인삼 열매 추출물은 인삼 열매의 과육 추출물, 인삼 열매의 과피 추출물 또는 인삼 열매의 과육 및 과피 추출물인 미토콘드리아 활성화를 위한 조성물.The method of claim 1,
The ginseng fruit extract is a composition for mitochondrial activation, which is a pulp extract of ginseng fruit, a rind extract of ginseng fruit or a pulp and rind extract of ginseng fruit.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20090135459 | 2009-12-31 | ||
KR1020090135459 | 2009-12-31 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020130052500A Division KR20130064761A (en) | 2009-12-31 | 2013-05-09 | Composition for activating mitochondria containing ginseng berry extracts |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20110079564A true KR20110079564A (en) | 2011-07-07 |
Family
ID=44918887
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020100139838A KR20110079564A (en) | 2009-12-31 | 2010-12-31 | Composition for activating mitochondria containing ginseng berry extracts |
KR1020130052500A KR20130064761A (en) | 2009-12-31 | 2013-05-09 | Composition for activating mitochondria containing ginseng berry extracts |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020130052500A KR20130064761A (en) | 2009-12-31 | 2013-05-09 | Composition for activating mitochondria containing ginseng berry extracts |
Country Status (1)
Country | Link |
---|---|
KR (2) | KR20110079564A (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013051904A2 (en) * | 2011-10-07 | 2013-04-11 | 주식회사 지바이오믹스 | Composition for preventing and treating vision deterioration and age-related macular degeneration through retinal repair using ginseng/red ginseng extracts and ginsenoside |
WO2014163328A1 (en) * | 2013-04-02 | 2014-10-09 | (주)아모레퍼시픽 | Composition for brain activation, comprising ginseng berry extract |
WO2014163402A1 (en) * | 2013-04-02 | 2014-10-09 | 주식회사 아모레퍼시픽 | Composition for improving health and quality of life of women containing ginseng berry extract |
CN104208507A (en) * | 2014-08-22 | 2014-12-17 | 何贞芳 | Acupoint sticking therapy paste for preventing and treating infantile convulsion |
CN104436049A (en) * | 2014-12-08 | 2015-03-25 | 刘世民 | Traditional Chinese medicine composition for treating heart disease |
KR20190107454A (en) | 2018-03-12 | 2019-09-20 | (주)모아캠 | Composition Containing Euryale ferox Seed Extract for Anti-Aging of the Skin and Reinforcement of Skin Barrier Function |
KR20190108777A (en) * | 2018-03-15 | 2019-09-25 | 숙명여자대학교산학협력단 | Compositions for muscle regeneration containing Ginsenoside Rb1 and Rb2 as active ingedients |
KR102078832B1 (en) * | 2018-08-20 | 2020-02-19 | 주식회사 홀리스틱바이오 | Pharmaceutical composition for prevention or treatment of muscular disease comprising Panax ginseng berry extract as an active ingredient |
KR20200107523A (en) * | 2019-03-08 | 2020-09-16 | 주식회사 한국인삼공사 | Pharmaceutical Composition Comprising Extracts of Ginseng and Ginseng Berry for Preventing or Treating Muscle Disease |
KR20220095926A (en) * | 2020-12-30 | 2022-07-07 | 주식회사 홀리스틱바이오 | Pharmaceutical composition for prevention or treatment of macular degeneration comprising panax ginseng berry extract |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150021699A1 (en) * | 2013-07-18 | 2015-01-22 | International Business Machines Corporation | FIN Field Effect Transistors Having Multiple Threshold Voltages |
US20150021698A1 (en) * | 2013-07-18 | 2015-01-22 | International Business Machines Corporation | Intrinsic Channel Planar Field Effect Transistors Having Multiple Threshold Voltages |
KR101751392B1 (en) | 2015-05-22 | 2017-06-29 | 한국과학기술원 | Method for screening regulator of mitochondrial fission |
KR20170005216A (en) * | 2015-07-01 | 2017-01-12 | 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 | Method for screening activator of mitochondria activity |
KR102088282B1 (en) * | 2017-09-21 | 2020-03-13 | 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 | Method for screening activator of mitochondria activity |
-
2010
- 2010-12-31 KR KR1020100139838A patent/KR20110079564A/en active Search and Examination
-
2013
- 2013-05-09 KR KR1020130052500A patent/KR20130064761A/en active Search and Examination
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013051904A2 (en) * | 2011-10-07 | 2013-04-11 | 주식회사 지바이오믹스 | Composition for preventing and treating vision deterioration and age-related macular degeneration through retinal repair using ginseng/red ginseng extracts and ginsenoside |
WO2013051904A3 (en) * | 2011-10-07 | 2013-09-19 | 주식회사 지바이오믹스 | Composition for preventing and treating vision deterioration and age-related macular degeneration through retinal repair using ginseng/red ginseng extracts and ginsenoside |
CN113244282A (en) * | 2013-04-02 | 2021-08-13 | 株式会社爱茉莉太平洋 | Brain-activating composition comprising ginseng fruit extract |
WO2014163402A1 (en) * | 2013-04-02 | 2014-10-09 | 주식회사 아모레퍼시픽 | Composition for improving health and quality of life of women containing ginseng berry extract |
KR20140120264A (en) * | 2013-04-02 | 2014-10-13 | (주)아모레퍼시픽 | Composition for brain activation comprising ginseng fruits extract |
CN104095894A (en) * | 2013-04-02 | 2014-10-15 | 株式会社爱茉莉太平洋 | Composition for brain activation, comprising ginseng berry extract |
US10383904B2 (en) | 2013-04-02 | 2019-08-20 | Amorepacific Corporation | Composition for improving health and quality of life of women containing ginseng berry extract |
US10555983B2 (en) | 2013-04-02 | 2020-02-11 | Amorepacific Corporation | Composition for brain activation, comprising ginseng fruit extract |
CN104870003A (en) * | 2013-04-02 | 2015-08-26 | 株式会社爱茉莉太平洋 | Composition for improving health and quality of life of women containing ginseng berry extract |
JP2016515611A (en) * | 2013-04-02 | 2016-05-30 | 株式会社アモーレパシフィックAmorepacific Corporation | Brain-activating composition containing ginseng fruit extract |
JP2016515613A (en) * | 2013-04-02 | 2016-05-30 | 株式会社アモーレパシフィックAmorepacific Corporation | A composition for improving the health and quality of life of women, containing ginseng seed extract |
EP2982377A4 (en) * | 2013-04-02 | 2016-10-26 | Amorepacific Corp | Composition for improving health and quality of life of women containing ginseng berry extract |
WO2014163328A1 (en) * | 2013-04-02 | 2014-10-09 | (주)아모레퍼시픽 | Composition for brain activation, comprising ginseng berry extract |
CN104208507B (en) * | 2014-08-22 | 2017-08-25 | 锦州紫金药业有限公司 | A kind of acupuncture points external application cream for preventing and treating child convulsion |
CN104208507A (en) * | 2014-08-22 | 2014-12-17 | 何贞芳 | Acupoint sticking therapy paste for preventing and treating infantile convulsion |
CN104436049A (en) * | 2014-12-08 | 2015-03-25 | 刘世民 | Traditional Chinese medicine composition for treating heart disease |
KR20190107454A (en) | 2018-03-12 | 2019-09-20 | (주)모아캠 | Composition Containing Euryale ferox Seed Extract for Anti-Aging of the Skin and Reinforcement of Skin Barrier Function |
KR20190108777A (en) * | 2018-03-15 | 2019-09-25 | 숙명여자대학교산학협력단 | Compositions for muscle regeneration containing Ginsenoside Rb1 and Rb2 as active ingedients |
KR102078832B1 (en) * | 2018-08-20 | 2020-02-19 | 주식회사 홀리스틱바이오 | Pharmaceutical composition for prevention or treatment of muscular disease comprising Panax ginseng berry extract as an active ingredient |
WO2020040432A1 (en) * | 2018-08-20 | 2020-02-27 | 주식회사 홀리스틱바이오 | Pharmaceutical composition for preventing or treating muscle diseases, containing ginseng berry extract as active ingredient |
US11612629B2 (en) | 2018-08-20 | 2023-03-28 | Holistic Bio Co., Ltd. | Pharmaceutical composition for preventing or treating muscle diseases, containing ginseng berry extract as active ingredient |
KR20200107523A (en) * | 2019-03-08 | 2020-09-16 | 주식회사 한국인삼공사 | Pharmaceutical Composition Comprising Extracts of Ginseng and Ginseng Berry for Preventing or Treating Muscle Disease |
KR20220095926A (en) * | 2020-12-30 | 2022-07-07 | 주식회사 홀리스틱바이오 | Pharmaceutical composition for prevention or treatment of macular degeneration comprising panax ginseng berry extract |
WO2022145813A1 (en) * | 2020-12-30 | 2022-07-07 | 주식회사 홀리스틱바이오 | Composition for preventing or treating macular degeneration containing ginseng berry extract |
Also Published As
Publication number | Publication date |
---|---|
KR20130064761A (en) | 2013-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20110079564A (en) | Composition for activating mitochondria containing ginseng berry extracts | |
KR101381112B1 (en) | Preparation method for fermented rhodiola rosea using red ginseng and composition for fatigue recovery and improvement of exercise performance comprising the fermented rhodiola rosea | |
CN101248873A (en) | Drinking food product with sight protection function | |
EP3075384B1 (en) | Anti-obesity composition | |
CN103211259A (en) | Anti-fatigue vitamin health care beverage and preparation method thereof | |
KR101326005B1 (en) | Functional beverage composition comprising Panax Ginseng concentrate and fruit concentrate | |
WO2012157790A1 (en) | Composition containing ginseng berry extract for activating mitochondria | |
KR101093998B1 (en) | Functional composition for the prevention of hangover and improving liver function | |
KR20210098225A (en) | A composition for diabetes or cardiovascular disease treatment comprising a citrus fermented kombucha | |
KR20130130995A (en) | A preparation method of an effervescent tablet comprising an extract of kyungokgo or crude drug | |
KR101918249B1 (en) | A composition for sleep induction comprising extract of rice bran and Sarcodon aspratus | |
KR101951402B1 (en) | Fermentative product of Sagunjatang having brain neuron cell-protective activity and uses thereof | |
KR101559483B1 (en) | Neuroprotective composition comprising extracts or fractions of seaweed as an active ingredient | |
KR100848686B1 (en) | A FERMENTED GINSENG COMPOSITION STRENGTHENED SIMULTANEOUSLY WITH γ-AMINOBUTYRIC ACID AND BIOCONVERSION SAPONIN BY LACTIC ACID BACTERIA | |
KR100919134B1 (en) | Extract of antiobestic ginseng with anti-obesity effect comprising high concentration of less polar ginsenoid and method of preparing the same | |
KR101271538B1 (en) | Composition for prevention and improvement of obesity comprised of organic acid, L-carnitine, L-arginine and nicotinamide | |
KR101344189B1 (en) | A Composition comprising an extract of fermented or non-fermented Lonicerae Flos and Citri Reticulatae Pericarpium for treating or preventing obesity | |
KR20200137193A (en) | A composition for improving, preventing and treating obesity and metabolic disease comprising polysaccharide fraction isolated from barley leaf | |
KR20140072418A (en) | Composition for Improving Obesity | |
KR100537954B1 (en) | Composition activating and protecting brain fuctions | |
KR20120005111A (en) | Athletic ability enhancing composition comprising licorice extracts and preparation method thereof | |
KR102501329B1 (en) | Method for processing plum with improved anti-cancer activity, anti-diabetes activity and effectiveness in improving blood lipid and processed plum using the same | |
KR20130091387A (en) | Red ginseng sport beverage comprising panax ginseng concentrate and fruit concentrate | |
TWI838919B (en) | Uses of golden passion fruit ferment for improving skin condition and anti-photoaging | |
EP3578587B1 (en) | Novel compound hexadecaphlorethol isolated from ishige okamurae and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
A107 | Divisional application of patent | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
J201 | Request for trial against refusal decision | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20140127 Effective date: 20150811 |